Company / Free Cash Flow
Apellis Pharmaceuticals, Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$45.0M
FY2025
5-year range
-$595.5M / $45.0M
FY2021-FY2025
Trend
+151.0%
vs FY2024
Sector context
#55 of 194
Health Care
What the data says
At $45M, Apellis Pharmaceuticals, Inc.'s free cash flow ranks #55 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 7 years, ranging from -$596M in FY2023 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025.
Improved from -$596M to $45M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#55 of 194 in Health CareTop 28% of 194This company $45.0M Sector average $470.6M
▼
-90.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 151.0% year-over-year.
- Ranks #55 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.0M | +151.0% |
| FY2024 | -$88.3M | +85.2% |
| FY2023 | -$595.5M | -15.6% |
| FY2022 | -$515.3M | +8.7% |
| FY2021 | -$564.2M | -240.1% |
| FY2020 | -$165.9M | +22.0% |
| FY2019 | -$212.8M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026